How I diagnose and treat thrombocytopenia in geriatric patients

2.

Piel-Julian

ML

,

Mahévas

M

,

Germain

J

, et al.

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults

.

J Thromb Haemost

.

2018

;

16

(

9

):

1830

-

1842

.

3.

Aguayo

GA

,

Donneau

A-F

,

Vaillant

MT

, et al.

Agreement between 35 published frailty scores in the general population

.

Am J Epidemiol

.

2017

;

186

(

4

):

420

-

434

.

4.

Moccia

AA

,

Thieblemont

C

.

Curing diffuse large B-cell lymphomas in elderly patients

.

Eur J Intern Med

.

2018

;

58

:

14

-

21

.

5.

Kenney

B

,

Stack

G

.

Drug-induced thrombocytopenia

.

Arch Pathol Lab Med

.

2009

;

133

(

2

):

309

-

314

.

6.

Swain

F

,

Bird

R

.

How I approach new onset thrombocytopenia

.

Platelets

.

2020

;

31

(

3

):

285

-

290

.

7.

Danese

MD

,

Lindquist

K

,

Gleeson

M

,

Deuson

R

,

Mikhael

J

.

Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura

.

Am J Hematol

.

2009

;

84

(

10

):

631

-

635

.

8.

Poordad

F

,

Theodore

D

,

Sullivan

J

,

Grotzinger

K

.

Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia

.

J Med Econ

.

2011

;

14

(

2

):

194

-

206

.

9.

An

R

,

Wang

PP

.

Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012

.

Vasc Health Risk Manag

.

2017

;

13

:

15

-

21

.

10.

Stasi

R

.

How to approach thrombocytopenia

.

Hematology Am Soc Hematol Educ Program

.

2012

;

2012

(

1

):

191

-

197

.

11.

Greinacher

A

,

Selleng

S

.

How I evaluate and treat thrombocytopenia in the intensive care unit patient

.

Blood

.

2016

;

128

(

26

):

3032

-

3042

.

12.

Aster

RH

,

Curtis

BR

,

McFarland

JG

,

Bougie

DW

.

Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management

.

J Thromb Haemost

.

2009

;

7

(

6

):

911

-

918

.

13.

Al-Nouri

ZL

,

Reese

JA

,

Terrell

DR

,

Vesely

SK

,

George

JN

.

Drug-induced thrombotic microangiopathy: a systematic review of published reports

.

Blood

.

2015

;

125

(

4

):

616

-

618

.

14.

Savage

RA

.

Pseudoleukocytosis due to EDTA-induced platelet clumping

.

Am J Clin Pathol

.

1984

;

81

(

3

):

317

-

322

.

15.

Pons

I

,

Monteagudo

M

,

Lucchetti

G

, et al.

Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocytopenia

.

Eur J Haematol

.

2010

;

85

(

2

):

158

-

163

.

16.

Miyazaki

K

,

Taira

M

,

Togano

T

, et al.

Immature platelet fraction in different diagnosis of thrombocytopenic states: an approach to distinguish idiopathic thrombocytopenic purpura from myelodysplastic syndrome with isolated thrombocytopenia

.

Blood

.

2006

;

108

(

11

):

1085

.

17.

Arnold

DM

,

Nazi

I

,

Warkentin

TE

, et al.

Approach to the diagnosis and management of drug-induced immune thrombocytopenia

.

Transfus Med Rev

.

2013

;

27

(

3

):

137

-

145

.

18.

Williamson

DR

,

Albert

M

,

Heels-Ansdell

D

, et al.

Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes

.

Chest

.

2013

;

144

(

4

):

1207

-

1215

.

19.

Strauss

R

,

Wehler

M

,

Mehler

K

,

Kreutzer

D

,

Koebnick

C

,

Hahn

EG

.

Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome

.

Crit Care Med

.

2002

;

30

(

8

):

1765

-

1771

.

20.

Wall

C

,

Moore

J

,

Thachil

J

.

Catheter-related thrombosis: a practical approach

.

J Intensive Care Soc

.

2015

;

17

(

2

):

160

-

167

.

21.

Cassidy

CA

,

Peterson

P

,

Cirera

L

,

Roychowdhury

DF

.

Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule

.

Anticancer Drugs

.

2001

;

12

(

4

):

383

-

385

.

22.

Zauli

G

,

Vitale

M

,

Falcieri

E

, et al.

In vitro senescence and apoptotic cell death of human megakaryocytes

.

Blood

.

1997

;

90

(

6

):

2234

-

2243

.

23.

Kuter

DJ

.

Milestones in understanding platelet production: a historical overview

.

Br J Haematol

.

2014

;

165

(

2

):

248

-

258

.

24.

Aref

S

,

Mabed

M

,

Selim

T

,

Goda

T

,

Khafagy

N

.

Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia

.

Hematology

.

2004

;

9

(

5-6

):

351

-

356

.

25.

Dowling

MR

,

Josefsson

EC

,

Henley

KJ

,

Hodgkin

PD

,

Kile

BT

.

Platelet senescence is regulated by an internal timer, not damage inflicted by hits

.

Blood

.

2010

;

116

(

10

):

1776

-

1778

.

26.

DiMaggio

D

,

Anderson

A

,

Bussel

JB

.

Cytomegalovirus can make immune thrombocytopenic purpura refractory

.

Br J Haematol

.

2009

;

146

(

1

):

104

-

112

.

27.

Sukati

H

,

Watson

HG

,

Urbaniak

SJ

,

Barker

RN

.

Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura

.

Blood

.

2007

;

109

(

10

):

4528

-

4538

.

28.

McMillan

R

,

Wang

L

,

Tomer

A

,

Nichol

J

,

Pistillo

J

.

Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP

.

Blood

.

2004

;

103

(

4

):

1364

-

1369

.

29.

Li

S

,

Wang

L

,

Zhao

C

,

Li

L

,

Peng

J

,

Hou

M

.

CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura

.

Br J Haematol

.

2007

;

139

(

4

):

605

-

611

.

30.

Skeith

L

,

Baumann Kreuziger

L

,

Crowther

MA

,

Warkentin

TE

.

A practical approach to evaluating postoperative thrombocytopenia

.

Blood Adv

.

2020

;

4

(

4

):

776

-

783

.

31.

Hui

P

,

Cook

DJ

,

Lim

W

,

Fraser

GA

,

Arnold

DM

.

The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review

.

Chest

.

2011

;

139

(

2

):

271

-

278

.

32.

Aster

R

.

Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia

.

J Clin Invest

.

1966

;

45

(

5

):

645

-

657

.

33.

Rios

R

,

Sangro

B

,

Herrero

I

,

Quiroga

J

,

Prieto

J

.

The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis

.

Am J Gastroenterol

.

2005

;

100

(

6

):

1311

-

1316

.

34.

Neunert

C

,

Terrell

DR

,

Arnold

DM

, et al.

American Society of Hematology 2019 guidelines for immune thrombocytopenia

.

Blood Adv

.

2019

;

3

(

23

):

3829

-

3866

.

35.

Provan

D

,

Arnold

DM

,

Bussel

JB

, et al.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia

.

Blood Adv

.

2019

;

3

(

22

):

3780

-

3817

.

36.

Waisbren

J

,

Dinner

S

,

Altman

J

, et al.

Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia

.

Int J Hematol

.

2017

;

105

(

1

):

44

-

51

.

37.

Stasi

R

,

Sarpatwari

A

,

Segal

JB

, et al.

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

.

Blood

.

2009

;

113

(

6

):

1231

-

1240

.

38.

McMillan

R

,

Wang

L

,

Tani

P

.

Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP)

.

J Thromb Haemost

.

2003

;

1

(

3

):

485

-

491

.

39.

Slichter

SJ

,

Kaufman

RM

,

Assmann

SF

, et al.

Dose of prophylactic platelet transfusions and prevention of hemorrhage

.

N Engl J Med

.

2010

;

362

(

7

):

600

-

613

.

40.

Al-Samkari

H

,

Kuter

DJ

. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment.

2020

:

275

-

288

.

41.

Zhou

H

,

Fu

R

,

Wang

H

, et al.

Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China

.

Ann Hematol

.

2013

;

92

(

1

):

79

-

87

.

42.

Cortelazzo

S

,

Finazzi

G

,

Buelli

M

,

Molteni

A

,

Viero

P

,

Barbui

T

.

High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura

.

Blood

.

1991

;

77

(

1

):

31

-

33

.

43.

Moulis

G

,

Palmaro

A

,

Sailler

L

,

Lapeyre-Mestre

M

.

Corticosteroid risk function of severe infection in primary immune thrombocytopenia adults. A nationwide nested case-control study

.

PLoS One

.

2015

;

10

(

11

):

e0142217

.

44.

Wei

Y

,

Ji

X-b

,

Wang

Y-w

, et al.

High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial

.

Blood

.

2016

;

127

(

3

):

296

-

302

. quiz 370.

45.

Mithoowani

S

,

Gregory-Miller

K

,

Goy

J

, et al.

High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis

.

Lancet Haematol

.

2016

;

3

(

10

):

e489

-

e496

.

46.

Godeau

B

,

Chevret

S

,

Varet

B

, et al.

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial

.

Lancet

.

2002

;

359

(

9300

):

23

-

29

.

47.

Marie

I

,

Maurey

G

,

Hervé

F

,

Hellot

MF

,

Levesque

H

.

Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature

.

Br J Dermatol

.

2006

;

155

(

4

):

714

-

721

.

48.

Rodeghiero

F

,

Stasi

R

,

Gernsheimer

T

, et al.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

.

Blood

.

2009

;

113

(

11

):

2386

-

2393

.

49.

Kuter

DJ

,

Bussel

JB

,

Lyons

RM

, et al.

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

.

Lancet

.

2008

;

371

(

9610

):

395

-

403

.

50.

Jurczak

W

,

Chojnowski

K

,

Mayer

J

, et al.

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia

.

Br J Haematol

.

2018

;

183

(

3

):

479

-

490

.

51.

Michel

M

,

Wasser

J

,

Godeau

B

, et al.

Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia

.

Ann Hematol

.

2015

;

94

(

12

):

1973

-

1980

.

52.

González-López

TJ

,

Pascual

C

,

Álvarez-Román

MT

, et al.

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

.

Am J Hematol

.

2015

;

90

(

3

):

E40

-

E43

.

53.

Palandri

F

,

Rossi

E

,

Bartoletti

D

, et al.

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

.

Blood

.

2021

;

138

(

7

):

571

-

583

.

54.

Ghanima

W

,

Junker

P

,

Hasselbalch

HC

, et al.

Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents

.

Br J Haematol

.

2011

;

155

(

2

):

248

-

255

.

55.

Patel

VL

,

Mahévas

M

,

Lee

SY

, et al.

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

.

Blood

.

2012

;

119

(

25

):

5989

-

5995

.

56.

Khellaf

M

,

Charles-Nelson

A

,

Fain

O

, et al.

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

.

Blood

.

2014

;

124

(

22

):

3228

-

3236

.

57.

Bussel

J

,

Arnold

DM

,

Grossbard

E

, et al.

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials

.

Am J Hematol

.

2018

;

93

(

7

):

921

-

930

.

58.

Guan

Y

,

Wang

S

,

Xue

F

, et al.

Long-term results of splenectomy in adult chronic immune thrombocytopenia

.

Eur J Haematol

.

2017

;

98

(

3

):

235

-

241

.

59.

Gonzalez-Porras

JR

,

Escalante

F

,

Pardal

E

, et al.

Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia

.

Eur J Haematol

.

2013

;

91

(

3

):

236

-

241

.

60.

Park

YH

,

Yi

HG

,

Kim

CS

, et al.

Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study

.

Acta Haematol

.

2016

;

135

(

3

):

162

-

171

.

61.

Thai

L-H

,

Mahévas

M

,

Roudot-Thoraval

F

, et al.

Long-term complications of splenectomy in adult immune thrombocytopenia

.

Medicine

.

2016

;

95

(

48

):

e5098

.

62.

Kantarjian

H

,

Giles

F

,

List

A

, et al.

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

.

Cancer

.

2007

;

109

(

9

):

1705

-

1714

.

63.

Schanz

J

,

Tüchler

H

,

Solé

F

, et al.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

.

J Clin Oncol

.

2012

;

30

(

8

):

820

-

829

.

64.

Bonadies

N

,

Rovó

A

,

Porret

N

,

Bacher

U

.

When should we think of myelodysplasia or bone marrow failure in a thrombocytopenic patient? A practical approach to diagnosis

.

J Clin Med

.

2021

;

10

(

5

):

1026

.

65.

Al Ameri

A

,

Jabbour

E

,

Garcia-Manero

G

, et al.

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

.

Clin Lymphoma Myeloma Leuk

.

2011

;

11

(

2

):

237

-

241

.

66.

Kao

JM

,

McMillan

A

,

Greenberg

PL

.

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes

.

Am J Hematol

.

2008

;

83

(

10

):

765

-

770

.

67.

Li

W

,

Morrone

K

,

Kambhampati

S

,

Will

B

,

Steidl

U

,

Verma

A

.

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies

.

Leukemia

.

2016

;

30

(

3

):

536

-

544

.

68.

Bogdanović

AD

,

Janković

GM

,

Colović

M

,

Trpinać

D

,

Bumbasirević

V

.

Apoptosis in bone marrow of myelodysplastic syndrome patients

.

Blood

.

1996

;

87

(

7

):

3064

.

69.

Zwierzina

H

,

Rollinger-Holzinger

I

,

Nuessler

V

,

Herold

M

,

Meng

Y

.

Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes

.

Leukemia

.

1998

;

12

(

1

):

59

-

64

.

70.

Mittelman

M

,

Zeidman

A

.

Platelet function in the myelodysplastic syndromes

.

Int J Hematol

.

2000

;

71

(

2

):

95

-

98

.

71.

Konstantopoulos

K

,

Lauren

L

,

Hast

R

,

Reizenstein

P

.

Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome

.

Anticancer Res

.

1989

;

9

(

4

):

893

-

896

.

72.

AuBuchon

JP

,

Herschel

L

,

Roger

J

,

Murphy

S

.

Preliminary validation of a new standard of efficacy for stored platelets

.

Transfusion

.

2004

;

44

(

1

):

36

-

41

.

73.

Greenberg

PL

,

Stone

RM

,

Al-Kali

A

, et al.

NCCN Guidelines® Insights: myelodysplastic syndromes, version 3.2022: featured updates to the NCCN guidelines

.

J Natl Compr Canc Netw

.

2022

;

20

(

2

):

106

-

117

.

74.

Schiffer

CA

,

Bohlke

K

,

Delaney

M

, et al.

Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update

.

J Clin Oncol

.

2018

;

36

(

3

):

283

-

299

.

75.

Stanworth

SJ

,

Estcourt

LJ

,

Powter

G

, et al.

A no-prophylaxis platelet-transfusion strategy for hematologic cancers

.

N Engl J Med

.

2013

;

368

(

19

):

1771

-

1780

.

76.

Wandt

H

,

Schaefer-Eckart

K

,

Wendelin

K

, et al.

Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

.

Lancet

.

2012

;

380

(

9850

):

1309

-

1316

.

77.

Kantarjian

H

,

Issa

JPJ

,

Rosenfeld

CS

, et al.

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

.

Cancer

.

2006

;

106

(

8

):

1794

-

1803

.

78.

Silverman

LR

,

McKenzie

DR

,

Peterson

BL

, et al.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

.

J Clin Oncol

.

2006

;

24

(

24

):

3895

-

3903

.

79.

Prica

A

,

Sholzberg

M

,

Buckstein

R

.

Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials

.

Br J Haematol

.

2014

;

167

(

5

):

626

-

638

.

80.

Giagounidis

A

,

Mufti

GJ

,

Fenaux

P

, et al.

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

.

Cancer

.

2014

;

120

(

12

):

1838

-

1846

.

81.

Kantarjian

HM

,

Giles

FJ

,

Greenberg

PL

, et al.

Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

.

Blood

.

2010

;

116

(

17

):

3163

-

3170

.

82.

Dickinson

M

,

Cherif

H

,

Fenaux

P

, et al.

Azacitidine with or without eltrombopag for first-line treatment of intermediate-or high-risk MDS with thrombocytopenia

.

Blood

.

2018

;

132

(

25

):

2629

-

2638

.

83.

van den Bemt

PMLA

,

Meyboom

RHB

,

Egberts

ACG

.

Drug-induced immune thrombocytopenia

.

Drug Saf

.

2004

;

27

(

15

):

1243

-

1252

.

84.

Gerson

SL

,

Kaplan

SL

,

Bruss

JB

, et al.

Hematologic effects of linezolid: summary of clinical experience

.

Antimicrob Agents Chemother

.

2002

;

46

(

8

):

2723

-

2726

.

85.

Priziola

JL

,

Smythe

MA

,

Dager

WE

.

Drug-induced thrombocytopenia in critically ill patients

.

Crit Care Med

.

2010

;

38

(

suppl 6

):

S145

-

S154

.

86.

Greinacher

A

,

Fuerll

B

,

Zinke

H

, et al.

Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia

.

Blood

.

2009

;

114

(

6

):

1250

-

1253

.

87.

George

JN

,

Terrell

DR

,

Vesely

SK

,

Kremer Hovinga

JA

,

Lämmle

B

.

Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer

.

Presse Med

.

2012

;

41

(

3 pt 2

):

e177

-

e188

.

88.

Arepally

G

,

Bauer

KA

,

Bhatt

DL

, et al.

The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education

.

Crit Pathw Cardiol

.

2010

;

9

(

1

):

41

-

48

.

89.

Nusrat

S

,

Borogovac

A

,

George

JN

,

Curtis

BR

,

Reese

JA

.

Drug (vaccine)-induced thrombocytopenia 2021: diversity of pathogenesis and clinical features

.

Am J Hematol

.

2022

;

97

(

4

):

E162

-

E165

.

90.

Curtis

BR

.

Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms

.

Immunohematology

.

2014

;

30

(

2

):

55

-

65

.

91.

Arnold

DM

,

Kukaswadia

S

,

Nazi

I

, et al.

A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia

.

J Thromb Haemost

.

2013

;

11

(

1

):

169

-

176

.

92.

Arnold

D

,

Curtis

B

,

Bakchoul

T

;

Platelet Immunology Scientific Subcommittee of the International Society on Thrombosis and Hemostasis

.

Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH

.

J Thromb Haemost

.

2015

;

13

(

4

):

676

-

678

.

93.

Von Drygalski

A

,

Curtis

BR

,

Bougie

DW

, et al.

Vancomycin-induced immune thrombocytopenia

.

N Engl J Med

.

2007

;

356

(

9

):

904

-

910

.